IKT – inhibikase therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics (IKT) was upgraded by LADENBURG THALM/SH SH to "strong-buy".
Form PRE 14A Inhibikase Therapeutics, For: Jun 26
Form 8-K Inhibikase Therapeutics, For: Apr 07
Form S-8 Inhibikase Therapeutics,
Form 10-K Inhibikase Therapeutics, For: Dec 31
Form 8-K Inhibikase Therapeutics, For: Mar 26
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.